Market Report, "Venezuela Pharmaceuticals & Healthcare Report Q4 2015", published

From: Fast Market Research, Inc.
Published: Mon Sep 28 2015


The Venezuelan governments remaining protection of its domestic pharmaceutical and healthcare industries will hamper investor sentiment as the country remains critically reliant on foreign medicine and foreign aid. Venezuela's diminishing appeal will be compounded by the country's worsening political and economic landscapes, severe drug shortages, and severely limited affordability levels. For now, multinational pharmaceutical companies show no sign of retreat from the market, however, expectations for further deterioration of Venezuela's economy will likely see contracting investments in coming years.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1052997_venezuela_pharmaceuticals.aspx?afid=301

Pharmaceuticals: VEB51bn (USD8bn) in 2014 to VEB63bn (USD3bn) in 2015; +23.8% in local currency terms and -66.2% in US dollar terms. Forecast has been revised downward from Q 2 15 due to updated forecast data, reflecting real market growth.
Healthcare: VEB112bn (USD18bn) in 2014 to VEB138bn (USD6bn) in 2015; +23.0% in local currency terms and -66.4% in US dollar terms. Forecast has been revised downward from Q 2 15 due to updated forecast data, reflecting real market growth.

Risk/Reward Index

Venezuela comes eleventh in BMI's Risk/Reward Index matrix for Q315 in America, which ranks pharmaceutical markets according to their attractiveness to multinational drugmakers. Venezuela's pharmaceutical market is expected to grow at double-digit rates through to 2024 in local currency terms, but this is largely due to inflation. One integral factor hampering Venezuela's score is its intellectual property environment, as the country has not granted a pharmaceutical patent since 2003. Unsurprisingly, Venezuela was featured on the priority watch list of the US Trade Representative's Special 301 report in 2015. The country was placed on the list in 2005 and has appeared on it every year since.

Key Trends And Developments

The Venezuela Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Venezuela Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Venezuela pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Venezuela, to test other views - a key input for successful budgeting and strategic business planning in the Venezuelan pharmaceutical and healthcare market.
* Target business opportunities and risks in the Venezuelan pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »